Neoadjuvant Nab-Paclitaxel, Trastuzumab, and Pertuzumab for HER2+ Primary Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
Cancer 2022 Dec 14;[EPub Ahead of Print], SM Lavasani, G Somlo, SE Yost, PH Frankel, C Ruel, Y Cui, M Murga, A Tang, N Martinez, L Kruper, L Tumyan, D Schmolze, C Yeon, Y Yuan, JR Waisman, J MortimerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.